Last updated on November 2016

MAD Study Evaluating the Safety Tolerability and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)


Brief description of study

The present study is designed to assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects.

Detailed Study Description

This study will assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects. Approximately 5 ascending cohorts are planned with approximately 8 subjects per cohort (6 active, 2 placebo). Each subject will undergo screening (Day -28 to Day -2) and, if eligible, return to the unit on Day -1 when eligibility will be reconfirmed. Eligible subjects will be randomized in a 3:1 ratio to receive investigational medicinal product (IMP) N91115 (daily [QD] or every 12 hours [Q12H]) or matching placebo (QD or Q12H) for 7 days and will be followed for safety while housed in the clinical research unit (CRU) until discharge on Day 8. Pharmacokinetics will be followed from Study Day 1 through the morning of Study Day 8. The subjects will be discharged from the CRU and complete the post treatment withdrawal phase, including a follow-up phone call on Day 15.

Clinical Study Identifier: NCT02934139

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Robert Williams, MD

DaVita Clinical Research
Lakewood, CO United States
  Connect »